Stock Investing - StockBaggers.com

Cell Genesys treatment does well in combination trial (bizjournals.com)Cell Genesys Inc. said Thursday that a treatment for prostate cancer did well in an early stage clinical trial combining it with another treatment developed by Medarex Inc.

Medarex to Present at the BIO CEO and Investor Conference (PR Newswire)Medarex, Inc. announced today that it is scheduled to present at the BIO CEO and Investor Conference at 9:45 AM Eastern Time on February 13, 2007. The conference is being held at The Waldorf=Astoria Hotel in New York.

Cell Genesys, Medarex Show Combo Data (AP)Biotech drug developers Cell Genesys Inc. and Medarex Inc. said Thursday that data from an early stage clinical trial using both of the company’s drugs showed activity against tumors in prostate cancer patients.

Medarex to Announce 2006 Fourth Quarter and Year-End Financial Results on February 28, 2007 (PR Newswire)Medarex, Inc. is scheduled to announce its 2006 fourth quarter and year-end results on Wednesday, February 28, 2007 by press release after the financial markets close. Following the release, Medarex’s management expects to host a conference call and live audio webcast at 4:30 PM Eastern Time to discuss the financial results and other business matters.

Medarex Announces Sale of Shares in Genmab A/S (PR Newswire)Medarex, Inc. announced today that it has sold approximately 2.5 million shares of Genmab A/S which stock is traded on the Copenhagen Stock Exchange. The trade is expected to settle on February 21, 2007.

Cell Genesys and Medarex Announce Encouraging Follow-Up Results from a Phase 1 Combination Therapy Trial With GVAX(TM) Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody (PR Newswire)Cell Genesys, Inc. and Medarex, Inc. today announced encouraging follow-up data from the ongoing Phase 1 clinical trial of Cell Genesys’ GVAX immunotherapy for prostate cancer, administered in combination with Medarex’s fully human anti-CTLA-4 antibody, ipilimumab .

MEDX Stock Investing | Google Finance MEDX | Yahoo Finance MEDX

After the Close: UHS PETM LTD (AP)Aftermarket traders may have their eyes on a few big companies that will file their fourth-quarter results after the closing bell Wednesday.

Tween adds COO to board (bizjournals.com)Tween Brands Inc. has added its new president and chief operating officer to its board.

Business Events Scheduled for Wednesday (AP)Major business events and economic events scheduled for Wednesday: WASHINGTON — Commerce Department reports on gross domestic product, fourth quarter, preliminary, 8:30 a.m.

Limited Brands Invites You to Listen to Its Fourth Quarter and Full Year 2006 Conference Call (PR Newswire)In conjunction with Limited Brands’ fourth quarter and full year 2006 earnings release, you are invited to listen to a broadcast of the conference call live over the Internet on Thursday, March 1, 2007 at 9:00 a.m.

LTD Stock Investing | Google Finance LTD | Yahoo Finance LTD

Stock Market Gains After Steep Decline on TuesdayAfter suffering its steepest drop in nearly four years, the stock market showed some tentative signs of recovery today. Global markets continued to feel the fallout from Tuesday?s global dive.

Toyota to Build $1.3 Billion Plant in the Land of Elvis and HoneyToyota?s eighth assembly plant in North America will be in an area best known for being the birthplace of Elvis.

McAfee?s Ex-Lawyer IndictedThe former top lawyer of McAfee Inc. was charged with stock options tampering that muddied the finances of the computer security software maker.

Wal-Mart says NYSE finds no violationsCHICAGO (Reuters) - Wal-Mart Stores Inc. said on Wednesday the New York Stock Exchange advised it that it is not violating exchange rules, after a union pension fund asked NYSE regulators to probe whether pay consultants for the retailer are too cozy with its managers.

Overwhelmed by 401(k) options?Don’t let a big menu of investment choices weigh you down. Your first decision to make is how much time you want to spend monitoring your plan.

Don’t buy the rosy forecast from Lowe’sLowe’s is doing a reasonably good job of holding its own in the battered housing industry. But that doesn’t make its stock a good buy.

Stock Investing

American Capital Shares Up on 4Q Report (AP)Shares of investment firm American Capital Strategies Ltd. climbed Wednesday a day after reporting its fourth quarter profit more than tripled.

American Capital Declares Dividend (AP)American Capital Strategies Ltd. on Wednesday declared a regular quarterly dividend of 89 cents. This is an 11 percent increase over the first quarter 2006 regular dividend of 80 cents per share.

European Capital Invests euro 120 Million in Delsey (PR Newswire)European Capital S.A. SICAR announced today that it has invested euro 120 million in Delsey, a leading global luggage brand.

American Capital Invests $37.5 Million in Forest Alaska (PR Newswire)American Capital Strategies Ltd. announced today that in the fourth quarter of 2006 it invested $37.5 million in Forest Alaska Operating LLC, a subsidiary of Forest Oil Corporation, an oil and gas company engaged in the acquisition, exploration, development and production of reserves primarily in North America.

American Capital Reports $4.43 in 2006 Realized Earnings; American Capital Declares $0.89 Q1 2007 Dividend; Announces 2007 Dividend Guidance of $3.68 Per Share (PR Newswire)American Capital Strategies Ltd. announced today its first quarter 2007 dividend declaration, 2007 dividend and other guidance and its results for the fourth quarter and full year of 2006.

ACAS Stock Investing | Google Finance ACAS | Yahoo Finance ACAS

Sector Wrap: Biotechnology (AP)Shares of biotechnology companies fell sharply Tuesday, caught up in the severe downturn that punished all but a few shares in the U.S. stock markets.

Sector Wrap: Pharmaceuticals Fall (AP)Shares of major pharmaceutical companies dipped Tuesday as the Dow Jones industrials closed down more than 400 points, but a few glimmers of good news managed to keep the sector above most other industries.

AMGN Stock Investing | Google Finance AMGN | Yahoo Finance AMGN

BioMarin Announces Results From Phase 2 Clinical Study of 6R-BH4 in Poorly Controlled Hypertension (PR Newswire)BioMarin Pharmaceutical Inc. today announced results from its Phase 2a placebo-controlled double-blind study of 6R-BH4 in patients with poorly controlled hypertension.

BMRN Stock Investing | Google Finance BMRN | Yahoo Finance BMRN